EUVIMEDEUVIMED entdecken
Open Access

Differential responses of disease‐related GRIN variants located in pore‐forming M2 domain of N‐methyl‐D ‐aspartate receptor to FDA ‐approved inhibitors

Rui Song, Jin Zhang, Riley E Perszyk iD, Chad R Camp iD, Weiting Tang, Varun Kannan, Jia Li, Yuchen Xu, Jiahui Chen iD, Yinlong Li iD, Steven H Liang iD, Stephen F Traynelis iD und 1 weitere

Journal of Neurochemistry · 2024

DOI: 10.1111/jnc.15942 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Neurochemistry, 2024. Verfasst von Rui Song und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology and Chemical Biology, Emory University School of Medicine, Atlanta, Georgia, USA. Hauptthemen laut MEDLINE: Receptors, N-Methyl-D-Aspartate. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIA NIH HHS, NINDS NIH HHS, Eunice Kennedy Shriver National Institute of Child Health and Human Development.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

N‐methyl‐D‐aspartate receptors (NMDAR), ionotropic glutamate receptors, mediate a slow component of excitatory synaptic transmission in the central nervous system and play a key role in normal brain function and development. Genetic variations in GRIN genes encoding NMDAR subunits that alter the receptor's functional characteristics are associated with a wide range of neurological and neuropsychiatric conditions. Pathological GRIN variants located in the M2 re‐entrant loop lining the channel pore cause significant functional changes, the most consequential alteration being a reduction in voltage‐dependent Mg 2+ inhibition. Voltage‐dependent Mg 2+ block is a unique feature of NMDAR biology whereby channel activation requires both ligand binding and postsynaptic membrane depolarization. Thus, loss of NMDAR Mg 2+ block will have a profound impact on synaptic function and plasticity. Here, we choose 11 missense variants within the GRIN1 , GRIN2A , and GRIN2B genes that alter residues located in the M2 loop and significantly reduce Mg 2+ inhibition. Each variant was evaluated for tolerance to genetic variation using the 3‐dimensional structure and assessed for functional rescue pharmacology via electrophysiological recordings. Three FDA‐approved NMDAR drugs—memantine, dextromethorphan, and ketamine—were chosen based on their ability to bind near the M2 re‐entrant loop, potentially rectifying dysregulated NMDAR function by supplementing the reduced voltage‐dependent Mg 2+ block. These results provide insight of structural determinants of FDA‐approved NMDAR drugs at their binding sites in the channel pore and may further define conditions necessary for the use of such agents as potential rescue pharmacology. image

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Receptors, N-Methyl-D-AspartateHumansAnimalsExcitatory Amino Acid AntagonistsXenopus laevisMutation, MissenseNerve Tissue ProteinsKetamineDextromethorphanProtein DomainsGenetic Variation

Stichwörter der Autor:innen

GRINautismchannelopathyepilepsyintellectual disabilitytranslational study

Substanzen

Receptors, N-Methyl-D-AspartateExcitatory Amino Acid AntagonistsNerve Tissue ProteinsKetamineDextromethorphanGRIN1 protein, humanNR2B NMDA receptor

Autor:innen und Institutionen

  • Department of Pharmacology and Chemical Biology, Emory University School of Medicine, Atlanta, Georgia, USA.
  • Department of Radiology and Imaging Sciences, Emory University School of Medicine, Atlanta, Georgia, USA.
  • Center for Functional Evaluation of Rare Variants (CFERV), Emory University School of Medicine, Atlanta, Georgia, USA.
  • Emory Neurodegenerative Disease Center, Emory University School of Medicine, Atlanta, Georgia, USA.

ORCID-Profile: Riley E Perszyk, Chad R Camp, Jiahui Chen, Yinlong Li, Steven H Liang, Stephen F Traynelis, Hongjie Yuan

Förderung

  • NIA NIH HHS
  • NINDS NIH HHS
  • Eunice Kennedy Shriver National Institute of Child Health and Human Development
  • NICHD NIH HHS
  • Uplifting Athletes Young Investigator Draft
  • National Institute of Neurological Disorders and Stroke
  • National Institute on Aging

Zitieren

APA

Song, R., Zhang, J., Perszyk, R. E., Camp, C. R., Tang, W., Kannan, V., Li, J., Xu, Y., Chen, J., Li, Y., Liang, S. H., Traynelis, S. F., & Yuan, H. (2024). Differential responses of disease‐related GRIN variants located in pore‐forming M2 domain of N‐methyl‐D ‐aspartate receptor to FDA ‐approved inhibitors. Journal of Neurochemistry. https://doi.org/10.1111/jnc.15942

Vancouver

Song R, Zhang J, Perszyk RE, Camp CR, Tang W, Kannan V, et al. Differential responses of disease‐related GRIN variants located in pore‐forming M2 domain of N‐methyl‐D ‐aspartate receptor to FDA ‐approved inhibitors. Journal of Neurochemistry. 2024. doi:10.1111/jnc.15942

BibTeX
@article{Song2024,
  author = {Song, Rui and Zhang, Jin and Perszyk, Riley E and Camp, Chad R and Tang, Weiting and Kannan, Varun and Li, Jia and Xu, Yuchen and Chen, Jiahui and Li, Yinlong and Liang, Steven H and Traynelis, Stephen F and Yuan, Hongjie},
  title = {Differential responses of disease‐related GRIN variants located in pore‐forming M2 domain of N‐methyl‐D ‐aspartate receptor to FDA ‐approved inhibitors},
  journal = {Journal of Neurochemistry},
  year = {2024},
  doi = {10.1111/jnc.15942}
}
Kostenlos starten →